Biotechnology
CVS blows past estimates, hikes outlook as insurance business outperforms
A screen displays the logo and trading information for CVS at the New York Stock Exchange, March 24, 2026. Jeenah Moon | Reuters CVS Health on Wednesday blew past first-quarter earnings and revenue estimates and raised its 2026 guidance, as its once-troubled insurance business showed improvement. CVS, which operates the nation’s largest pharmacy chain, sees […]
Read More
Novo Nordisk stock jumps 6% after drugmaker hikes forcast as Wegovy pill sales smash forecasts
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk hiked its annual profit guidance on Wednesday, as the drugmaker said its Wegovy weight-loss pill performed better than expected in the first three months of the […]
Read More
FDA withdrew studies finding Covid, shingles vaccines were safe
The FDA blocked the publication of several studies supporting the safety of vaccines against Covid and shingles in recent months, a Health and Human Services Department spokesperson confirmed on Tuesday. It’s the latest effort by the Trump administration to challenge safe and effective shots in the U.S. and make them harder to access for some […]
Read More
Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth
Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press | Corbis News | Getty Images Pfizer on Tuesday posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as its recently launched and acquired products showed growth. Older top-selling drugs, including its blood thinner […]
Read More
Major health insurers show signs of recovery – but a key test looms
Piotr Swat | SOPA Images | Lightrocket | Getty Images Major health insurers appear to be off to an encouraging start this year — but a crucial test for the sector is still ahead. Solid first-quarter results have helped lift investor sentiment, even as insurers continue to grapple with higher medical costs. Companies including UnitedHealth, […]
Read More
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. Jason Reed | Reuters The Food and Drug Administration on Thursday proposed excluding the active ingredients in Novo Nordisk and Eli Lilly‘s blockbuster obesity and diabetes medications from the list of drugs that outsourcing facilities can use for compounding […]
Read More
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
David Ricks, chief executive officer of Eli Lilly & Co., at the Semafor World Economy Summit during the International Monetary Fund (IMF) and World Bank Spring meetings in Washington, DC, US, on Friday, April 17, 2026. Aaron Schwartz | Bloomberg | Getty Images Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past […]
Read More
UK’s biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
AstraZeneca and GSK, the U.K.’s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday. Source
Read More
Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss
Regeneron Pharmaceuticals will make its newly approved gene therapy for a rare, genetic form of hearing loss available for free in the U.S. The company hasn’t yet decided how much it will charge in other countries, Regeneron CEO Leonard Schleifer told CNBC on Friday. “We haven’t set a price yet, but they should pay their […]
Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]
Read More